Press Releases


Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine's Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine's comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tu...

Read More

Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company's Comprehensive Genomic Profiling Assay

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it has received payment from Palmetto GBA, the Company's Medicare Administrative Contractor (MAC) in North Carolina, for its FoundationOne comprehensive genomic profiling assay when used in the clinical course...

Read More

Foundation Medicine Receives FDA Approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca™ (rucaparib) for the Treatment of Women with Ovarian Cancer

--First and only companion diagnostic to detect tumor BRCA1/2 alterations, potentially increasing the number of women who are eligible for Rubraca (rucaparib) therapy-- --FDA approval of FoundationFocus CDxBRCA marks important progress towards Foundation Medicine's development of a compre...

Read More

... Next